Opdivo (nivolumab)

pCPA File Number: 21111
Negotiation Status:
Concluded with an LOI
Indication(s):
Melanoma adjuvant therapy
Sponsor/Manufacturer:
Bristol Myers Squibb Canada Inc.
CDA-AMC Project Number:
PC0147-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: